Translating cell therapies for neurodegenerative diseases: Huntington’s disease as a model disorder
Open Access
- 9 March 2022
- journal article
- review article
- Published by Oxford University Press (OUP) in Brain
- Vol. 145 (5) , 1584-1597
Abstract
There has been substantial progress in the development of regenerative medicine strategies for CNS disorders over the last decade, with progression to early clinical studies for some conditions. However, there are multiple challenges along the translational pipeline, many of which are common across diseases and pertinent to multiple donor cell types. These include defining the point at which the preclinical data are sufficiently compelling to permit progression to the first clinical studies; scaling-up, characterization, quality control and validation of the cell product; design, validation and approval of the surgical device; and operative procedures for safe and effective delivery of cell product to the brain. Furthermore, clinical trials that incorporate principles of efficient design and disease-specific outcomes are urgently needed (particularly for those undertaken in rare diseases, where relatively small cohorts are an additional limiting factor), and all processes must be adaptable in a dynamic regulatory environment.Here we set out the challenges associated with the clinical translation of cell therapy, using Huntington’s disease as a specific example, and suggest potential strategies to address these challenges. Huntington’s disease presents a clear unmet need, but, importantly, it is an autosomal dominant condition with a readily available gene test, full genetic penetrance and a wide range of associated animal models, which together mean that it is a powerful condition in which to develop principles and test experimental therapeutics. We propose that solving these challenges in Huntington’s disease would provide a road map for many other neurological conditions. This white paper represents a consensus opinion emerging from a series of meetings of the international translational platforms Stem Cells for Huntington’s Disease and the European Huntington’s Disease Network Advanced Therapies Working Group, established to identify the challenges of cell therapy, share experience, develop guidance and highlight future directions, with the aim to expedite progress towards therapies for clinical benefit in Huntington’s disease.Keywords
Funding Information
- Brain Repair And Intracranial Neurotherapeutics (BRAIN) Unit
- Centre for Trials Research
- European Union’s Seventh Framework Programme (602245)
- California Institute for Regenerative Medicine (PC1-08117, CLIN1-10953)
- National Institutes of Health
- Adelson Medical Research Foundation
- Novo Nordisk Foundation
- Lundbeck Foundation
- Olav Thon Foundation
- Lyrik Therapeutics and Sana Biotechnology (EDU1-10779)
This publication has 93 references indexed in Scilit:
- Devices for cell transplantation into the central nervous system: Design considerations and emerging technologiesSurgical Neurology International, 2013
- The Current Status of Neural Grafting in the Treatment of Huntington?s Disease. A ReviewFrontiers in Integrative Neuroscience, 2011
- Magnetic resonance imaging of Huntington's disease: preparing for clinical trialsNeuroscience, 2009
- Does neuroinflammation fan the flame in neurodegenerative diseases?Molecular Neurodegeneration, 2009
- Neural transplants in patients with Huntington's disease undergo disease-like neuronal degenerationProceedings of the National Academy of Sciences, 2009
- Striatal progenitors derived from human ES cells mature into DARPP32 neuronsin vitroand in quinolinic acid-lesioned ratsProceedings of the National Academy of Sciences, 2008
- Dopamine neurons implanted into people with Parkinson's disease survive without pathology for 14 yearsNature Medicine, 2008
- Alloimmunisation to Donor Antigens and Immune Rejection Following Foetal Neural Grafts to the Brain in Patients with Huntington's DiseasePLOS ONE, 2007
- Angiogenesis and the blood-brain barrier in intracerebral solid and cell suspension graftsSurgical Neurology, 1994
- Stereotactic Technique and Pathophysiological Mechanisms of Neurotransplantation in Huntington's ChoreaStereotactic and Functional Neurosurgery, 1992